Publications associées à Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Peptide-based virucidal drugs

Before the COVID-19 pandemic, viruses were not a major priority for the scientific community. Today, many events have changed the world and the importance of studying viruses, vaccines, and antiviral drugs is fully appreciated. The development of effective ...

EPFL2024

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

Philippe Colin, Aleksandar Antanasijevic

Neutralizing antibodies (NAbs) to multiple epitopes on the HIV-1-envelope glycoprotein (Env) have been isolated from infected persons. The potency of NAbs is measured more often than the size of the persistent fraction of infectivity at maximum neutralizat ...

Public Library Science2023

Poloxamers Have Vaccine-Adjuvant Properties by Increasing Dissemination of Particulate Antigen at Distant Lymph Nodes

Myriam Isabelle Lamrayah

Vaccine technology is still facing challenges regarding some infectious diseases, which can be addressed by innovative drug delivery systems. In particular, nanoparticle-based vaccines combined with new types of adjuvants are actively explored as a platfor ...

MDPI2023

Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma

Didier Trono, Priscilla Turelli, Marc Emmenegger

The clinical outcome of SARS-CoV-2 infections, which can range from asymptomatic to lethal, is crucially shaped by the concentration of antiviral antibodies and by their affinity to their targets. However, the affinity of polyclonal antibody responses in p ...

LIFE SCIENCE ALLIANCE LLC2022

Emerging dimensions of cellular cGAS-STING signaling

Andrea Ablasser, Baptiste Claude André Guey

The recognition of DNA through the cGAS-STING pathway plays a critical role in antiviral immunity, but can also drive maladaptive immune responses underlying several pathological conditions. Despite its importance, understanding the organization of cGAS-ST ...

2022

Identification of Vaccine Effects When Exposure Status Is Unknown

Mats Julius Stensrud

Results from randomized controlled trials (RCTs) help determine vaccination strategies and related public health policies. However, defining and identifying estimands that can guide policies in infectious disease settings is difficult, even in an RCT. The ...

2023

A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma

Didier Trono, Priscilla Turelli, Florence Pojer, Charlène Mireille Raymonde Raclot, Céline Pellaton, Valeria Cagno, Jérémy Campos

The detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies in the serum of an individual indicates previous infection or vaccination. However, it provides limited insight into the protective nature of this immune resp ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic

Francesco Stellacci

The COVID-19 outbreak has fueled a global demand for effective diagnosis and treatment as well as mitigation of the spread of infection, all through large-scale approaches such as specific alternative antiviral methods and classical disinfection protocols. ...

AMER CHEMICAL SOC2020

Adjuvant-free immunization with infective filarial larvae as lymphatic homing antigen carriers

Melody Swartz, Alexandre de Titta, Witold Waldemar Kilarski, Sachiko Hirosue, Marcela Rincón-Restrepo, Esra Güç, David Scott Wilson

Controlled infection with intestinal nematodes has therapeutic potential for preventing the symptoms of allergic and autoimmune diseases. Here, we engineered larvae of the filarial nematode Litomosoides sigmodontis as a vaccine strategy to induce adaptive ...

Nature Research2020

Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity

Davide Demurtas

Author summary Human cytomegalovirus (HCMV) infection is the foremost viral cause of congenital birth defects. Attempts to vaccinate against HCMV brought moderate, though not sufficient, reduction in infection. Moreover, phase II clinical trial with gB for ...

2020

Monitoring Tuberculosis Drug Activity in Live Animals by Using Near-Infrared Fluorescence Imaging

Stewart Cole, Raphael Christopher Sommer

Worldwide, tuberculosis (TB) is the leading cause of death due to infection with a single pathogenic agent, Mycobacterium tuberculosis. In the absence of an effective vaccine, new, more powerful antibiotics are required to halt the growing spread of multid ...

AMER SOC MICROBIOLOGY2019

Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity

Jeffrey Alan Hubbell, Melody Swartz, Sachiko Hirosue, Laura Jeanbart, Xavier Fredy René Quaglia-Thermes, David Scott Wilson, Giacomo Olimpio Diaceri, Maria Anna Sofia Broggi, Michal Mateusz Raczy, Ruyi Wang

Fully effective vaccines for complex infections must elicit a diverse repertoire of antibodies (humoral immunity) and CD8+ T-cell responses (cellular immunity). Here, we present a synthetic glyco-adjuvant named p(Man-TLR7), which, when conjugated to antige ...

NATURE PUBLISHING GROUP2019

Innovative Tools and in vivo Methods for Tuberculosis Drug Discovery and Development

Raphael Christopher Sommer

Worldwide, tuberculosis (TB) is the leading cause of death due to a single infectious agent, claiming 1.6 million human lives and causing >10 million new cases in 2017 alone, mostly in low-income regions. The intracellular pathogen Mycobacterium tuberculos ...

EPFL2019

Evaluation of oxidation-sensitive polymersomes as vaccine nanocarriers to enhance humoral responses against arenavirus envelope glycoproteins

Clara Galan Navarro

Vaccines currently represent one of the most effective means to control and prevent infectious diseases affecting humans and animals and have dramatically improved public health, quality of life, and life expectancy. Over the last years several conceptual ...

EPFL2017

Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein

Jeffrey Alan Hubbell, Melody Swartz, Sachiko Hirosue, Marcela Rincón-Restrepo, Clara Galan Navarro, Stefan Kunz

Lassa virus (LASV) causes severe hemorrhagic fever with high mortality, yet no vaccine currently exists. Antibodies targeting viral attachment proteins are crucial for protection against many viral infections. However, the envelope glycoprotein (GP) 1 of L ...

Academic Press Inc Elsevier Science2017

Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Sachiko Hirosue, Daniel Kenneth Bonner

Background: Newborns display distinct immune responses, leaving them vulnerable to infections and impairing immunization. Targeting newborn dendritic cells (DCs), which integrate vaccine signals into adaptive immune responses, might enable development of a ...

2017

An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy

Hyunjin Shim, Jeffrey David Jensen, Claudia Bank, Matthieu Foll, Sebastian Matuszewski

The rapid evolution of drug resistance remains a critical public health concern. The treatment of influenza A virus (IAV) has proven particularly challenging, due to the ability of the virus to develop resistance against current antivirals and vaccines. He ...

Wiley-Blackwell2016

MicroRNA Profile in CD8+T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression

Evaristo Jose Planet Letschert

Background The relationship between host microRNAs (miRNA), viral control and immune response has not yet been elucidated in the field of HIV. The aim of this study was to assess the differential miRNA profile in CD8+ T-cells between HIV-infected individua ...

Public Library of Science2016

Concerted Activity of IgG1 Antibodies and IL-4/IL-25-Dependent Effector Cells Trap Helminth Larvae in the Tissues following Vaccination with Defined Secreted Antigens, Providing Sterile Immunity to Challenge Infection

Nicola Harris, Julia Esser-von Bieren

Over 25% of the world's population are infected with helminth parasites, the majority of which colonise the gastrointestinal tract. However, no vaccine is yet available for human use, and mechanisms of protective immunity remain unclear. In the mouse model ...

Public Library of Science2015

Engineering synthetic vaccines using cues from natural immunity

Melody Swartz

Vaccines aim to protect against or treat diseases through manipulation of the immune response, promoting either immunity or tolerance. In the former case, vaccines generate antibodies and T cells poised to protect against future pathogen encounter or attac ...

Nature Publishing Group2013